At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
BIVI BioVie Inc
Not Yet Opened 11-21 16:00:00 EST
3.11
-0.25
-7.44%
盘后3.05
-0.06-1.93%
19:59 EST
High3.43Low3.00Vol3.21M
Open3.36D1 Closing3.36Amplitude12.73%
Mkt Cap55.23MTradable Cap47.62MTotal Shares17.76M
T/O10.19MT/O Rate20.97%Tradable Shares15.31M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
BioVie files to sell 7.71M shares of common stock for holders
seekingalpha  ·  06:36
BioVie files to sell 7.71M shares of common stock for holders
BioVie to Present Design of Planned Phase 2 Study of Bezisterim for the Treatment of Long COVID at the Demystifying Long COVID International Conference
GlobeNewswire  ·  11-20 21:00
BioVie to Present Design of Planned Phase 2 Study of Bezisterim for the Treatment of Long COVID at the Demystifying Long COVID International Conference
BioVie says Parkinson’s Disease clinical trial is fully funded
TIPRANKS  ·  11-04
BioVie says Parkinson’s Disease clinical trial is fully funded
BioVie Inc - Raises Over $15 Million From Secondary Offerings
THOMSON REUTERS  ·  11-04
BioVie Inc - Raises Over $15 Million From Secondary Offerings
BioVie Inc - Pd-202 Trial Expected to Start Early 2025, Results by Late 2025
THOMSON REUTERS  ·  11-04
BioVie Inc - Pd-202 Trial Expected to Start Early 2025, Results by Late 2025
BioVie’s Upcoming Parkinson’s Disease Clinical Trial Is Fully Funded
THOMSON REUTERS  ·  11-04
BioVie’s Upcoming Parkinson’s Disease Clinical Trial Is Fully Funded
BioVie’s Upcoming Parkinson’s Disease Clinical Trial is Fully Funded
GlobeNewswire  ·  11-04
BioVie’s Upcoming Parkinson’s Disease Clinical Trial is Fully Funded
BioVie Inc. Announces Closing of Registered Direct Offering
THOMSON REUTERS  ·  10-30
BioVie Inc. Announces Closing of Registered Direct Offering
BioVie Inc. Announces Closing of Registered Direct Offering
GlobeNewswire  ·  10-30
BioVie Inc. Announces Closing of Registered Direct Offering
BRIEF-BioVie Announces Pricing Of Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Reuters  ·  10-29
BRIEF-BioVie Announces Pricing Of Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Update -- BioVie Inc. Announces Pricing of Registered Direct Offering Priced at-the-Market Under Nasdaq Rules
THOMSON REUTERS  ·  10-29
Update -- BioVie Inc. Announces Pricing of Registered Direct Offering Priced at-the-Market Under Nasdaq Rules
BioVie 1.15M share registered direct offering priced at $2.83
TIPRANKS  ·  10-29
BioVie 1.15M share registered direct offering priced at $2.83
BioVie Inc. Announces Pricing of Registered Direct Offering Priced at-the-Market Under Nasdaq Rules
THOMSON REUTERS  ·  10-29
BioVie Inc. Announces Pricing of Registered Direct Offering Priced at-the-Market Under Nasdaq Rules
BioVie Inc - Prices Direct Offering of 1,146,000 Shares at $2.83 Each
THOMSON REUTERS  ·  10-29
BioVie Inc - Prices Direct Offering of 1,146,000 Shares at $2.83 Each
BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
GlobeNewswire  ·  10-29
BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
BioVie Inc. Announces Closing of Registered Direct Offering and Concurrent Private Placement
THOMSON REUTERS  ·  10-25
BioVie Inc. Announces Closing of Registered Direct Offering and Concurrent Private Placement
BioVie 2.667M share registered direct offering priced at $2.25
TIPRANKS  ·  10-24
BioVie 2.667M share registered direct offering priced at $2.25
BRIEF-BioVie Inc Prices Direct Offering Of 2.7 Mln Shares At $2.25 Each
Reuters  ·  10-24
BRIEF-BioVie Inc Prices Direct Offering Of 2.7 Mln Shares At $2.25 Each
BioVie Inc. Announces Pricing of Registered Direct Offering and Concurrent Private Placement Priced at-the-Market Under Nasdaq Rules
THOMSON REUTERS  ·  10-24
BioVie Inc. Announces Pricing of Registered Direct Offering and Concurrent Private Placement Priced at-the-Market Under Nasdaq Rules
BioVie Inc - Prices Direct Offering of 2.7 Mln Shares at $2.25 Each
THOMSON REUTERS  ·  10-24
BioVie Inc - Prices Direct Offering of 2.7 Mln Shares at $2.25 Each

Introduction

Company Name.
BioVie Inc
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.
Issue price:
--